REGN - Spark Newswire

1 minute read

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $728

Today, 2:22 AM

Truist Securities analyst Robyn Karnauskas maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $754 to $728.

REGN

1 minute read

10 Biggest Price Target Changes For Tuesday

By Lisa Levin

Today, 2:22 AM

Keybanc raised Take-Two Interactive Software, Inc. (NASDAQ: TTWO) price target from $185 to $190. Take-Two Interactive shares fell 2.8% to $170.21 in pre-market trading.

CRNC

1 minute read

Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $605

By Benzinga Newsdesk

Today, 2:22 AM

Morgan Stanley maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $585 to $605.

REGN

2 minute read

Cathie Wood’s Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings

By Shanthi Rexaline

Today, 2:22 AM

Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed.

ARKG

1 minute read

Regeneron’s Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales

By Vandana Singh

Today, 2:22 AM

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned

REGN

1 minute read

Recap: Regeneron Pharmaceuticals Q4 Earnings

By Benzinga Insights

Today, 2:22 AM

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

REGN